10-Q: Solsence Reports Q1 2026 Results, Revenue Declines

Solsence, Inc. reported a decrease in total revenue for the first quarter of 2026 compared to the prior year, driven by lower sales in consumer products and advanced materials.

Summary

• Solsence, Inc. reported total revenue of $12.96 million for the first quarter ended March 31, 2026, a decrease from $14.63 million in the same period of 2025.
• Product revenue, the main revenue driver, also declined to $12.92 million from $14.58 million year-over-year.
• The company experienced a net loss of $0.77 million for the quarter, compared to a net income of $0.08 million in Q1 2025.
• Cost of revenue decreased to $9.62 million from $11.24 million, primarily due to decreased volume leading to lower labor and material costs.
• Research and development expenses increased slightly to $1.04 million from $1.02 million, attributed to higher legal costs and salaries.
• Selling, general, and administrative expenses rose to $2.80 million from $2.11 million, also due to increased legal and employee-related costs.
• The company ended the quarter with $0.57 million in cash, down from $1.29 million at the end of 2025.
• Net cash provided by operating activities was $1.52 million for the quarter, a significant improvement from a use of $7.22 million in Q1 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, a shift from profit to loss, and increased operating expenses, despite some improvements in cash flow from operations.

Positives

• Net cash provided by operating activities improved significantly to $1.52 million in Q1 2026 from a negative $7.22 million in Q1 2025.
• Cost of revenue decreased by $1.62 million, primarily due to decreased volume leading to lower labor and material costs.
• The company has a strong focus on innovation in skin health and beauty markets with proprietary technologies.
• The company's securities were uplisted to Nasdaq under the symbol SLSN on April 8, 2025.

Negatives

• Total revenue decreased by $1.67 million to $12.96 million in Q1 2026 compared to $14.63 million in Q1 2025.
• Product revenue decreased by $1.66 million to $12.92 million in Q1 2026 compared to $14.58 million in Q1 2025.
• The company reported a net loss of $0.77 million in Q1 2026, a reversal from a net income of $0.08 million in Q1 2025.
• Selling, general, and administrative expenses increased by $0.69 million to $2.80 million in Q1 2026.
• Cash balance decreased to $0.57 million as of March 31, 2026, from $1.29 million as of December 31, 2025.
• The company relies heavily on a few significant customers, with the top three accounting for 67% of revenue in Q1 2026, up from 42% in Q1 2025.

Risks

• Dependence on a limited number of key customers, with a decision by a customer to cancel a purchase order or supply agreement posing a risk.
• Potential inability to obtain working capital when needed on acceptable terms or at all.
• The company may be required to sell production equipment to BASF if performance requirements are not met.
• Uncertain demand for and acceptance of Solsence products and advanced materials.
• The impact of competitive products and technologies.
• Dependence on patents and protection of proprietary information.
• Potential new governmental regulations, especially concerning nanomaterials, could be costly to comply with.
• Business interruptions due to unexpected events or public health crises.
• The resolution of litigation or other legal proceedings.
• Inflationary pressures on supplier prices and wages may materially affect operations and financial position in 2026 and beyond.
• Potential limitations on the utilization of federal net operating loss carryforwards due to ownership changes.

Future Outlook

The company expects that as product revenue volume increases, fixed manufacturing costs will be more efficiently absorbed, leading to increased margins. Their most critical operational issue is reducing controllable variable product manufacturing costs. Capital spending for 2026 is expected to be between $0.5 million and $1.5 million, funded by operations, existing credit lines, and possible new debt financing.

Management Comments

• Total revenue decreased to $12,957 for the three months ended March 31, 2026, compared to $14,625 for the same period in 2025.
• The decrease for the three months in the cost of revenue was primarily driven by decreased volume resulting in decreased labor and material costs.
• Our planning has had us adding to our current fixed manufacturing cost structure through 2026 to accommodate additional growth, and to build a better base for further growth beyond that level.
• Our most critical operational issue today is reducing controllable variable product manufacturing costs.
• We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow.
• We expect supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2026 and beyond.

Industry Context

StockSavvy.ai notes that Solsence's performance in Q1 2026, with declining revenues and a net loss, contrasts with the general growth often seen in the beauty and life sciences sectors. The company's focus on skin health and personal care ingredients places it in competitive markets where innovation and cost management are crucial. The increased reliance on a few key customers highlights a common challenge for smaller companies in securing stable revenue streams.

Comparison to Industry Standards

• The revenue decline of approximately 11.4% for Solsence in Q1 2026 is concerning when compared to the broader personal care and cosmetics market, which has shown resilience and growth in recent periods.
• Competitors in the advanced materials sector, particularly those supplying to medical diagnostics, may be experiencing different demand trends, though Solsence notes a decrease in demand for its own medical diagnostics ingredients.
• The company's gross margin of approximately 25.7% in Q1 2026 is lower than many established players in the specialty chemical and consumer product ingredient space, which often achieve margins above 40-50%.

Legal Proceedings

• None mentioned in the filing.

Related Party Transactions

• The company has outstanding balances and credit facilities with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, a majority shareholder.
• Outstanding balances with Beachcorp, LLC were $12,547,000 as of March 31, 2026.
• Outstanding balances with Strandler, LLC were $1,000,000 as of March 31, 2026.
• Related party interest expense was $263,000 for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders: The net loss and declining revenue may negatively impact shareholder value and confidence.
• Creditors: The decrease in cash and continued reliance on related party debt facilities may be a concern for creditors.
• Customers: The company's reliance on a few key customers could lead to supply chain disruptions if those relationships change.
• Employees: Increased legal and employee-related costs could impact future compensation or staffing levels.

Next Steps

• Continue to monitor and manage supplier price increases and wage/benefit inflation.
• Focus on reducing controllable variable product manufacturing costs.
• Increase manufacturing capacity and cost efficiency through greater scale.
• Expand marketing and sales efforts for Solsence products.
• Develop new product formulations and related new technologies.
• Continue to improve core technologies to enhance manufacturing operations and reduce costs.
• Manage potential sale of production equipment to BASF if performance requirements are not met.

Key Dates

Recommendation

While the Q1 2026 results show a decline in revenue and a return to net loss, the significant improvement in operating cash flow and the company's strategic focus on innovation in the growing skin health market warrant a hold. Investors should monitor cost management, customer diversification, and the successful scaling of production.

Keywords

Solsence, 10-Q, Quarterly Report, Financial Statements, Revenue, Net Loss, Skin Health, Personal Care Ingredients, Consumer Products, Advanced Materials, SEC Filing